Literature DB >> 18177584

JNC-7 guidelines: are they still relevant?

William C Cushman1.   

Abstract

The recommendations of the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), published in 2003, are largely relevant today. Lowering blood pressure (BP) to goal in hypertensive patients is of primary importance in reducing cardiovascular risk. Antihypertensive drugs vary in their efficacy to lower BP and can have BP-independent effects on cardiovascular events, as seen especially with regard to preventing heart failure and stroke. Thiazide-type diuretics were recommended as the preferred initial drugs for treatment of hypertension in most patients, and this is still an appropriate recommendation. Several other classes were recommended as next in priority, but beta-blockers should now have a lesser role in the management of uncomplicated hypertension. Although a new JNC report would be reassuring to practitioners and should include some changes since JNC 7, I consider most of the recommendations to still be relevant today.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18177584     DOI: 10.1007/s11906-007-0070-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  32 in total

1.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

2.  Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.

Authors:  Clive Rosendorff; Henry R Black; Christopher P Cannon; Bernard J Gersh; Joel Gore; Joseph L Izzo; Norman M Kaplan; Christopher M O'Connor; Patrick T O'Gara; Suzanne Oparil
Journal:  Circulation       Date:  2007-05-14       Impact factor: 29.690

3.  The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

Authors:  Paula T Einhorn; Barry R Davis; Barry M Massie; William C Cushman; Linda B Piller; Lara M Simpson; Daniel Levy; Chuke E Nwachuku; Henry R Black
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

4.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

5.  Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.

Authors: 
Journal:  JAMA       Date:  1970-08-17       Impact factor: 56.272

6.  Effect of ramipril on the incidence of diabetes.

Authors:  Jackie Bosch; Salim Yusuf; Hertzel C Gerstein; Janice Pogue; Patrick Sheridan; Gilles Dagenais; Rafael Diaz; Alvaro Avezum; Fernando Lanas; Jeffrey Probstfield; George Fodor; Rury R Holman
Journal:  N Engl J Med       Date:  2006-09-15       Impact factor: 91.245

7.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

8.  Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000.

Authors:  Kurt J Greenlund; Janet B Croft; George A Mensah
Journal:  Arch Intern Med       Date:  2004-10-25

9.  Prehypertension and cardiovascular disease risk in the Women's Health Initiative.

Authors:  Judith Hsia; Karen L Margolis; Charles B Eaton; Nanette K Wenger; Matthew Allison; LieLing Wu; Andrea Z LaCroix; Henry R Black
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

10.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

View more
  1 in total

1.  One more look at guidelines for primary and secondary prevention of cardiovascular disease in women.

Authors:  Genovefa Kolovou; Apostolia Marvaki; Helen Bilianou
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.